Irbesartán Liconsa (Irbesartan)

Irbesartan blocks the AT1 receptors that bind angiotensin II, a hormone that narrows blood vessels and stimulates aldosterone release. By preventing this binding, the drug relaxes vascular smooth muscle, reduces vasoconstriction, and decreases fluid retention, leading to lower systemic blood pressure.

The appropriate dose of Irbesartán Liconsa is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other concurrent medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Irbesartán Liconsa is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy. Limited data are available for breastfeeding; therefore, the drug is generally not recommended for nursing mothers unless the benefit outweighs the potential risk.

To place an order, submit an enquiry on the Irbesartán Liconsa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irbesartán Liconsa belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers or diuretics, ARBs provide a distinct mechanism focused on the renin‑angiotensin system, making them useful in patients with diabetic kidney disease.

Store Irbesartán Liconsa at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight, and sources of heat to maintain its stability and potency.

Irbesartán Liconsa is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include angioedema, severe hyperkalemia, and acute kidney injury, especially when combined with other drugs that affect potassium levels or renal function. Patients should be monitored for swelling of the face or throat, sudden rise in serum potassium, and changes in kidney function.

Irbesartán Liconsa should be avoided in patients with known hypersensitivity to irbesartan or any component of the formulation, in pregnant women, and in individuals with severe hepatic impairment. Caution is also advised for patients with bilateral renal artery stenosis or those taking interacting medications without proper monitoring.